Author: Geoffrey Horwitz

Digital health: The next blockbuster

(Pyh2/Wikimedia Commons)
(Pyh2/Wikimedia Commons)

Geoffrey Horwitz, PhD, is a business development associate in the Technology and Innovation Development Office (TIDO) at Boston Children’s Hospital. Follow him on Twitter @GeoffHorwitz

At the recent 2014 Biotechnology Industry Organization (BIO) International Convention, the message was clear: Digital health is the new blockbuster. For the first time ever, BIO spotlighted digital health, with a specific focus on how digital health is influencing the pharmaceutical and biotech industries. Also featured was a digital health zone where companies and other exhibitors from all over the world could demo their products and services to thousands of attendees.

In pharmaceutical lingo, a blockbuster is a drug that generates revenues of at least $1 billion. Digital health certainly fits this definition. By 2018, reports suggest that revenues will exceed $6 billion for wearable wireless devices alone. A recent McKinsey study found that 75 percent of consumers surveyed, of various ages and located throughout the world, would like to use digital health devices.

Read Full Story | Leave a Comment

Developing cures for neglected diseases: Overcoming the barriers

(scottchan/Fotolia.com)
Who will invest in the clinical development of drugs that offer limited commercial opportunities?(scottchan/Fotolia.com)
The desire to impact areas of great need drives many academic medical researchers. Unfortunately, a variety of challenges can prevent even the most promising innovations and technologies from reaching the patients who would benefit most. When the target population is primarily in the developing world, these challenges are magnified. Only a fraction of research and development funding goes toward treatments that target neglected diseases and the needs of low- and middle-income countries, posing a particularly frustrating situation.

The Universities Allied for Essential Medicines (UAEM)’s recent forum on Global Access Licensing of Biomedically Relevant Technologies delved into this pressing issue. According to the UAEM philosophy, the accessibility of medicine to developing nations “depends critically on how universities manage their intellectual property.” Further, the UAEM suggests that obtaining patents means that “anyone who can’t afford the asking price will be unable to access the product” and that “further innovation is hampered or outright blocked.”

In contrast, many of the panelists at the forum didn’t see intellectual property licensing as the primary obstacle—rather, they viewed it as a requirement to attract industry partners.

Read Full Story | Leave a Comment